BioKDE: Biomedical Knowledge Discovery Engine
Sorted by:  
Results by Year
Article Type
Publication date


Custom range



  399,474 results (0.317 seconds)
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
Shu-Lian Wang, Hui Fang, +18 authors, Ye-Xiong Li.
Lancet Oncol. 2019 Jan 30; 20(3):352-360. PMID: 30711522
Highly Cited.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Kenji Tamura, Junji Tsurutani, +14 authors, Shanu Modi.
Lancet Oncol. 2019 Apr 29; 20(6):816-826. PMID: 31047803
Highly Cited.
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
Harold J Burstein, Christina Lacchetti, +9 authors, Jennifer J Griggs.
J Clin Oncol. 2016 Feb 16; 34(14):1689-701. PMID: 26884586
Highly Cited. Systematic Review. Review.
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Sharon H Giordano, Sarah Temin, +15 authors, American Society of Clinical Oncology.
J Clin Oncol. 2014 May 05; 32(19):2078-99. PMID: 24799465     Free PMC article
Highly Cited. Systematic Review. Review.
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
Sukhbinder Dhesy-Thind, Glenn G Fletcher, +9 authors, Catherine H Van Poznak.
J Clin Oncol. 2017 Mar 06; 35(18):2062-2081. PMID: 28618241
Highly Cited. Systematic Review. Review.
European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer.
Icro Meattini, Carlotta Becherini, +19 authors, Charlotte E Coles.
Lancet Oncol. 2022 Jan 02; 23(1):e21-e31. PMID: 34973228
Review.
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Gnant, Georg Pfeiler, +17 authors, Austrian Breast and Colorectal Cancer Study Group.
Lancet Oncol. 2019 Feb 19; 20(3):339-351. PMID: 30795951
Highly Cited.
Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.
M Lambertini, M Ceppi, +9 authors, L Del Mastro.
Ann Oncol. 2015 Sep 07; 26(12):2408-19. PMID: 26347105
Highly Cited. Review.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, +11 authors, American Society of Clinical Oncology.
J Clin Oncol. 2016 Feb 08; 34(10):1134-50. PMID: 26858339     Free PMC article
Highly Cited. Review.
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Luca Gianni, Giancarlo Bisagni, +8 authors, Giuseppe Viale.
Lancet Oncol. 2018 Jan 08; 19(2):249-256. PMID: 29326029
Highly Cited.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Helena M Earl, Louise Hiller, +30 authors, PERSEPHONE Steering Committee and Trial Investigators.
Lancet. 2019 Jun 06; 393(10191):2599-2612. PMID: 31178152     Free PMC article
Highly Cited.
Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA).
Laura Biganzoli, Hans Wildiers, +12 authors, Riccardo Audisio.
Lancet Oncol. 2012 Mar 30; 13(4):e148-60. PMID: 22469125
Highly Cited. Review.
Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
Alfredo Berruti, Vito Amoroso, +7 authors, Maria Pia Sormani.
J Clin Oncol. 2014 Oct 27; 32(34):3883-91. PMID: 25349292
Highly Cited. Review.
Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG).
Laura Biganzoli, Nicolò Matteo Luca Battisti, +15 authors, Etienne G C Brain.
Lancet Oncol. 2021 May 14; 22(7):e327-e340. PMID: 34000244
Review.
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), S Darby, +13 authors, R Peto.
Lancet. 2011 Oct 19; 378(9804):1707-16. PMID: 22019144     Free PMC article
Highly Cited. Review.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, +16 authors, Charles E Geyer.
Lancet Oncol. 2018 Feb 28; 19(4):497-509. PMID: 29501363
Highly Cited.
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Peter Schmid, Hope S Rugo, +13 authors, IMpassion130 Investigators.
Lancet Oncol. 2019 Nov 27; 21(1):44-59. PMID: 31786121
Highly Cited.
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Cristina Saura, Dominik Hlauschek, +23 authors, Evandro de Azambuja.
Lancet Oncol. 2019 Aug 08; 20(9):1226-1238. PMID: 31402321
Highly Cited.
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet. 2019 Feb 08; 393(10179):1440-1452. PMID: 30739743     Free PMC article
Highly Cited.
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Maria Vittoria Dieci, Nina Radosevic-Robin, +26 authors, International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Semin Cancer Biol. 2017 Oct 09; 52(Pt 2):16-25. PMID: 29024776
Highly Cited. Review.
Previous 1 2 3 4 5 6 7 8 9 10